Bristol Myers Earnings Are a ‘Tale of 2 Trends’ as Guidance Falls Short. The Stock Is Falling
Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price gain of more than 20%, while most of the group has been flat or down. Financial results the company reported early Thursday seem to validate that recent performance,
Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses Expectations
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2024, with sales up 7.5% year on year to $12.34 billion. On the other hand, the company’s full-year revenue guidance of $45.
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
1don MSN
Q4 2024 Management View CEO Chris Boerner highlighted a robust performance in Q4 2024, driven by double-digit growth in the company’s growth portfolio, including key products like Breyanzi, Camzyos, ...
Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...
Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal ...
The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.
Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...
Bristol Myers Squibb Co. forecast 2025 sales and profit below Wall Street’s expectations — a sign that declining sales of ...
As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback